Galápagos NV
| Naamloze vennootschap | |
| Traded as |
Euronext: GLPG OTCQX: GLPG |
| Industry | Pharmaceutical |
| Founded | 1999 |
| Headquarters | Mechelen, Belgium |
Key people | Onno van de Stolpe (CEO), Raj Parekh (Chairman) |
| Products | filgotinib; GLPG1205; GLPG0778 |
| Revenue | €160 million (2013)[1] |
| €152 million (2013)[1] | |
| Total assets | €111 million (2013)[1] |
| Total equity | €141 million (2013)[1] |
Number of employees | 400[2] |
| Website | www.glpg.com |
Galápagos NV is a Belgian pharmaceutical research company which was founded in 1999. The company started as a joint venture between Crucell and Tibotec.[3] Currently it has drugs under investigation against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis and systemic lupus erythematosus. The stocks are traded at Euronext Amsterdam under ticker GLPG and at the U.S. OTC market under the ticker symbol GLPYY. The CEO is the Dutchman Onno van de Stolpe.
Drugs currently under development
- Filgotinib (GLPG0634) a selective inhibitor of JAK1 (Janus kinase 1) being developed for the treatment of rheumatoid arthritis and potentially Crohn's disease.
- GLPG1205: a first-in-class GPR84-inhibitor currently under research for the treatment of inflammatory bowel disease.
- GLPG0778 and GLPG0555: a drug developed in alliance with GlaxoSmithKline and currently being researched as a treatment agenst systemic lupus erythematosus, psoriasis and ulcerative colitis.
External links
Coordinates: 51°03′19″N 4°27′08″E / 51.05528°N 4.45222°E
References
- ↑ 1.0 1.1 1.2 1.3 "Gálapagos Annual Report 2013" (PDF). Gálapagos. Retrieved 26 February 2015.
- ↑ http://www.glpg.com/
- ↑ http://www.glpg.com/index.php/aboutus/aboutus/